3-(p-Fluorobenzoyloxy)tropane

3-(p-Fluorobenzoyloxy)tropane
Clinical data
Routes of
administration
insufflated
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
Identifiers
IUPAC name
  • (1R,5S)-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-fluorobenzoate
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC15H18FNO2
Molar mass263.312 g·mol−1
3D model (JSmol)
SMILES
  • CN1C2CC(OC(C3=CC=C(F)C=C3)=O)CC1CC2
InChI
  • InChI=1S/C15H18FNO2/c1-17-12-6-7-13(17)9-14(8-12)19-15(18)10-2-4-11(16)5-3-10/h2-5,12-14H,6-9H2,1H3 checkY
  • Key:YXDFSLSXLYAAPF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

3β-(p-Fluorobenzoyloxy)tropane, (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4-fluorobenzoic acid ester, 4-fluorotropacocaine, 3-Pseudotropyl-4-fluorobenzoate, 3-pseudotropyl-4-fluorobenzoate, pFBT) is a tropane derivative drug which acts as a local anaesthetic, having around 30% the stimulant potency of cocaine but around the same potency as a local anaesthetic. It has been investigated as a potential radiolabelled agent for studying receptor binding,[1] but was not adopted for this application. The main application for fluorotropacocaine, however, has been as a designer drug analogue of cocaine, first detected by the EMCDDA in 2008,[2][3] and subsequently sold as an ingredient of various "bath salt" powder products, usually mixed in combination with other stimulant drugs such as caffeine, dimethocaine, desoxypipradrol or substituted cathinone derivatives.[4]

See also

References

  1. Ali M. Emran. New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control. Springer, 1991. p84. ISBN 0-306-44035-0
  2. Wohlfarth A, Weinmann W (May 2010). "Bioanalysis of new designer drugs". Bioanalysis. 2 (5): 965–79. doi:10.4155/bio.10.32. PMID 21083227.
  3. Kavanagh P, Angelov D, O'Brien J, Fox J, O'Donnell C, Christie R, et al. (January 2012). "The syntheses and characterization 3β-(4-fluorobenzoyloxy)tropane (fluorotropacocaine) and its 3α isomer". Drug Testing and Analysis. 4 (1): 33–8. doi:10.1002/dta.362. PMID 22102564.
  4. Reitzel LA, Dalsgaard PW, Müller IB, Cornett C (May 2012). "Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish internet company". Drug Testing and Analysis. 4 (5): 342–54. doi:10.1002/dta.358. PMID 22102551.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.